Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 961-967

  Cheng, Hsueh Tsen ^a   Hung, Wen Chun ^b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

c Cbl; Histone deacetylase; Suberoylanilide hydroxamic acid; Tie2 tyrosine kinase; Ubiquitin proteasome pathway

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CBL PROTEIN; MESSENGER RNA; PROTEASOME; TIE 1 RECEPTOR; UBIQUITIN; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEFENSE MECHANISM; GENE SILENCING; HUMAN; HUMAN CELL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

ANGIOPOIETINS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HISTONE DEACETYLASE INHIBITORS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; LYMPHANGIOGENESIS; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, TIE-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

EID: 84879621346     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2523     Document Type: Article

References (36)

1. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006. (Pubitemid 43054973)
2. Inche AG and La Thangue NB: Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today 11: 97-109, 2006. (Pubitemid 43375960)
3. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25: 3109-3115, 2007. (Pubitemid 47218059)
4. Duvic M and Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120, 2007. (Pubitemid 47074165)
5. Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol 33: 637-646, 2008.
6. Zhao Y, Tan J, Zhuang L, et al: Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090-16095, 2005. (Pubitemid 41552872)
7. WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004.
8. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
9. Woan KV, Sahakian E, Sotomayor EM, Seto E and Villagra A: Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 90: 55-65, 2012.
10. Blanchard F and Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197-204, 2005. (Pubitemid 40222231)
11. Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002. (Pubitemid 34123805)
12. Alitalo K: The lymphatic vasculature in disease. Nat Med 17: 1371-1380, 2011.
13. Achen MG, McColl BK and Stacker SA: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7: 121-127, 2005. (Pubitemid 40248338)
14. Cao R, Björndahl MA, Religa P, et al: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6: 333-345, 2004. (Pubitemid 39361435)
15. Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177, 2009.
16. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997. (Pubitemid 27450643)
17. Yuan HT, Khankin EV, Karumanchi SA and Parikh SM: Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29: 2011-2022, 2009.
18. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG and Koh GY: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552, 2000.
19. Murray BW, Padrique ES, Pinko C and McTigue MA: Mechanistic effects of autophosphorylation on receptor tyrosine kinase catalysis: enzymatic characterization of Tie2 and phospho-Tie2. Biochemistry 40: 10243-10253, 2001. (Pubitemid 32800131)
20. Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS and Dumont DJ: A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol 23: 2658-2668, 2003. (Pubitemid 36403068)
21. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K and Dumont DJ: Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem 274: 30896-30905, 1999.
22. Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R and Witte M: Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol 319: 309-320, 2008.
23. Shimoda H, Bernas MJ, Witte MH, Gale NW, Yancopoulos GD and Kato S: Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res 328: 329-337, 2007. (Pubitemid 46452201)
24. Kajiya K, Kidoya H, Sawane M, Matsumoto-Okazaki Y, Yamanishi H, Furuse M and Takakura N: Promotion of lymphatic integrity by angiopoietin-1/Tie2 signaling during inflammation. Am J Pathol 180: 1273-1282, 2012.
25. Pan MR, Chang TM, Chang HC, Su JL, Wang HW and Hung WC: Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci 122: 3358-3364, 2009.
26. Wehrle C, Van Slyke P and Dumont DJ: Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation. Biochem J 423: 375-380, 2009.
27. Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002. (Pubitemid 34123805)
28. Ugur HC, Ramakrishna N, Bello L, et al: Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83: 267-275, 2007. (Pubitemid 46952237)
29. Mühlethaler-Mottet A, Meier R, Flahaut M, et al: Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 7: 55, 2008.
30. Chou CW and Chen CC: HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 582: 4059-4065, 2008.
31. Cheng HT and Hung WC: Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. Oncol Rep 29: 1238-1244, 2013.
32. Huang H, Bhat A, Woodnutt G and Lappe R: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585, 2010.
33. Oliner J, Min H, Leal J, et al: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516, 2004. (Pubitemid 39469986)
34. Shimamoto G, Gegg C, Boone T and Quéva C: Peptibodies: A flexible alternative format to antibodies. MAbs 4: 586-591, 2012.
35. Beck A and Reichert JM: Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3: 415-416, 2011.
36. Herbst RS, Hong D, Chap L, et al: Safety, pharmacokinetics and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27: 3557-3565, 2009.